ND Grows in Rare Disease Research

Brandi Klingerman | July 1, 2016   

Rich Taylor Feature

Those with NGLY1 deficiency cannot synthesize the enzyme N-glycanase and present with varying symptoms including developmental delays, movement disorders, diminished reflexes, and more.

However, the symptom each NGLY1 deficiency child has in common is their inability to produce tears. For the past year, Taylor has led a group of Notre Dame researchers working to develop a treatment for this rare disease in collaboration with the Grace Science Foundation and the pharmaceutical company, Retrophin, Inc.This coming fall, McCourtney Hall will open as the first dedicated interdisciplinary research building at the University of Notre Dame. Richard Taylor, professor of chemistry and biochemistry, was part of a team who managed the development and construction of the new building. 

Read more here.

 by Daily Domer Staff

Posted In: Features